Anti-CD138 mAbs [OC-46F2](MABL-711)

MABL-711

WB, Block, ELISA, FC, IF, IHC

Engineer antibody

Human

OC-46F2

Recombinant Antibody

This antibody is specific for the extracellular domain of human syndecan-1. Syndecan-1 is a cell membrane protein that, after its shedding by heparanase enzymes, is accumulated in the extracellular matrix of some tumours, e.g. myeloma and lung carcinoma, where it modulates several key processes of tumourigenesis such as cancer cell proliferation and apoptosis, angiogenesis and metastasis.

Syndecan-1; SDC1; SYND1; SDC

P18827

The original antibody was generated by selecting a human antibody phage display library from human melanoma cells and later on its by its expression in mammalian cells..

The original antibody inhibited vascular maturation and tumour growth in an experimental human melanoma model. The therapeutic efficacy of this antibody was also demonstrated in an experimental ovarian carcinoma model. OC-46F2 scFv version was used as a capture antibody in a solid phase sandwich ELISA (PMID: 26460958). The scFv version of this antibody was also used in the immunofluorescent and immunohistochemical analysis of melanoma tissues, human ovarian carcinomas, human normal ovary cells and SKMEL28 cells (PMID: 26460958, 26460958). Syndecan-1 expression on a panel of cell lines was analysed by flow cytometry using recombinant OC-46F2. The scFv antibody can also recognize purified human recombinant extracellular portion of syndecan-1 in a western blot assay. Mice treated with OC-46F2 scFv showed no co-distribution of syndecan-1 with vascular endothelial growth factor receptor 2 (VEGFR2), which is generally seen in intratumour melanoma microenvironment. (PMID: 23352437). Melanoma cells lose their ability to form tubule-like structures in vitro after blocking syndecan- 1 using OC-46F2. In a human melanoma xenograft model the combined therapy using OC-46F2 and L19- IL2, an immunocytokine specific for the tumor angiogenic-associated B-fibronectin isoform(B-FN), led to a complete inhibition of tumor growth until day 90 from tumor implantation in 71% of treated mice (PMID: 26460958). The small immuno protein version of this antibody 46F2SIP was used in combination with L19-IL2 for combination therapy in a human ovarian carcinoma model (PMID: 31443604).

Orecchia et al. A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma. Eur J Cancer. 2013 May;49(8):2022-33. PMID:23352437

Describes the generation of this antibody and tests its therapeutic efficacy in an experimental ovarian carcinoma model.

100 μg Purified antibody.

1 mg/ml.

Protein A affinity purified

PBS with 0.02% Proclin 300.

Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.